Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Abbvie Inc 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 USA

www.abbvie.com P: 847-932-7900

Description:

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

Key Statistics

Overview:

Market Capitalization, $K 300,692,000
Enterprise Value, $K 347,263,008
Shares Outstanding, K 1,765,868
Annual Sales, $ 54,318 M
Annual Net Income, $ 4,863 M
Last Quarter Sales, $ 12,310 M
Last Quarter Net Income, $ 1,369 M
EBIT, $ 12,787 M
EBITDA, $ 21,485 M
60-Month Beta 0.64
% of Insider Shareholders 0.25%
% of Institutional Shareholders 70.23%
Float, K 1,761,453
% Float 99.75%
Short Volume Ratio 0.65

Growth:

1-Year Return 23.54%
3-Year Return 44.92%
5-Year Return 148.44%
5-Year Revenue Growth 65.84%
5-Year Earnings Growth 40.46%
5-Year Dividend Growth 64.90%

Per-Share Information:

Most Recent Earnings 2.31 on 04/26/24
Next Earnings Date 07/25/24
Earnings Per Share ttm 10.96
EPS Growth vs. Prev Qtr -17.20%
EPS Growth vs. Prev Year -6.10%
Annual Dividend Rate, $ 6.06
Annual Dividend Yield 3.56%
Most Recent Dividend 1.550 on 07/15/24
Next Ex-Dividends Date 07/15/24
Dividend Payable Date 08/15/24
Dividend Payout Ratio 54.48%

ABBV Ratios

Ratio
Price/Earnings ttm 15.50
Price/Earnings forward 15.51
Price/Earnings to Growth 2.16
Return-on-Equity % 179.47%
Return-on-Assets % 14.05%
Profit Margin % 8.95%
Debt/Equity 9.20
Price/Sales 5.52
Price/Cash Flow 10.74
Price/Book 37.29
Book Value/Share 4.56
Interest Coverage 4.71

ABBV Dividends

Date Value
07/15/24 $1.5500
04/12/24 $1.5500
01/12/24 $1.5500
10/12/23 $1.4800
07/13/23 $1.4800
04/13/23 $1.4800
01/12/23 $1.4800
10/13/22 $1.4100
07/14/22 $1.4100
04/13/22 $1.4100
01/13/22 $1.4100
10/14/21 $1.3000
07/14/21 $1.3000
04/14/21 $1.3000
01/14/21 $1.3000
10/14/20 $1.1800
07/14/20 $1.1800
04/14/20 $1.1800
01/14/20 $1.1800
10/11/19 $1.0700
07/12/19 $1.0700
04/12/19 $1.0700
01/14/19 $1.0700
10/12/18 $0.9600
07/12/18 $0.9600
04/12/18 $0.9600
01/11/18 $0.7100
10/12/17 $0.6400
07/12/17 $0.6400
04/11/17 $0.6400
01/11/17 $0.6400
10/12/16 $0.5700
07/13/16 $0.5700
04/13/16 $0.5700
01/13/16 $0.5700
10/13/15 $0.5100
07/13/15 $0.5100
04/13/15 $0.5100
01/13/15 $0.4900
10/10/14 $0.4200
07/11/14 $0.4200
04/11/14 $0.4200
01/13/14 $0.4000
10/10/13 $0.4000
07/11/13 $0.4000
04/11/13 $0.4000
01/11/13 $0.4000
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar